{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:42Z","timestamp":1792898922332,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200\u2010mg parenteral dose. Because of oritavancin's long half\u2010life and broad gram\u2010positive activity, interest in its use for other infections is high.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a retrospective cohort evaluation of patients receiving oritavancin at a single academic medical center. All patients receiving more than one dose of oritavancin were included. Patients were excluded if therapy was interrupted by more than 14 days. Efficacy, defined a priori as clinical success, improvement, or failure, and adverse drug effect outcomes were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen patients received multiple oritavancin doses (range 2\u201318 doses) for the treatment of complicated infections including osteomyelitis, surgical site infection, intravascular infections, and pneumonia. All patients achieved clinical success or improvement with oritavancin. Four patients (24%) had an adverse event requiring oritavancin discontinuation that reversed rapidly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Off\u2010label oritavancin use may be a safe and effective alternative to daily antibiotic infusions to treat complicated infectious disease processes. This study is limited by small sample size and retrospective design, but it provides information on using oritavancin in these complex gram\u2010positive infections.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2057","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T13:36:40Z","timestamp":1510234600000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Multiple\u2010Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections"],"prefix":"10.1002","volume":"38","author":[{"given":"Lucas T","family":"Schulz","sequence":"first","affiliation":[{"name":"University of Wisconsin Health Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Dworkin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dela\u2010Pena","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center Columbus Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren E.","family":"Rose","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Pharmacy Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.mmi_17061143.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu778"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310422"},{"issue":"1","key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","article-title":"Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200\u2010milligram dose for 3 days or a single 800\u2010milligram dose","volume":"49","author":"Fetterly GJ","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.06.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1405078"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1641"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp126"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw451"},{"issue":"4","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long\u2010half\u2010life lipoglycopeptide","volume":"60","author":"Saravolatz LD","year":"2015","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00981-15"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv156"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1957"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0156-z"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw173"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.014"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00285-12"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.268"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:49:30Z","timestamp":1761061770000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/phar.2057"],"URL":"https:\/\/doi.org\/10.1002\/phar.2057","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]},"assertion":[{"value":"2017-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}